Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Jan 18, 2022

SELL
$5.37 - $7.07 $1.18 Million - $1.56 Million
-220,670 Closed
0 $0
Q3 2021

Nov 09, 2021

SELL
$5.54 - $7.51 $742,720 - $1.01 Million
-134,065 Reduced 37.79%
220,670 $1.36 Million
Q2 2021

Aug 16, 2021

BUY
$7.78 - $11.4 $2.76 Million - $4.04 Million
354,735 New
354,735 $3.19 Million

Others Institutions Holding AFMD

About Affimed N.V.


  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $185M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track M&G Investment Management LTD Portfolio

Follow M&G Investment Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of M&G Investment Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on M&G Investment Management LTD with notifications on news.